JPWO2019224713A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019224713A5 JPWO2019224713A5 JP2020565399A JP2020565399A JPWO2019224713A5 JP WO2019224713 A5 JPWO2019224713 A5 JP WO2019224713A5 JP 2020565399 A JP2020565399 A JP 2020565399A JP 2020565399 A JP2020565399 A JP 2020565399A JP WO2019224713 A5 JPWO2019224713 A5 JP WO2019224713A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tmeff2
- antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims description 248
- 108090001123 antibodies Proteins 0.000 claims description 248
- 239000000427 antigen Substances 0.000 claims description 182
- 102000038129 antigens Human genes 0.000 claims description 182
- 108091007172 antigens Proteins 0.000 claims description 182
- 102100018591 TMEFF2 Human genes 0.000 claims description 69
- 101710023903 TMEFF2 Proteins 0.000 claims description 69
- 201000011510 cancer Diseases 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 206010060862 Prostate cancer Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 229920000023 polynucleotide Polymers 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 235000004279 alanine Nutrition 0.000 claims description 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003638 reducing agent Substances 0.000 claims description 6
- 230000036947 Dissociation constant Effects 0.000 claims description 4
- 238000009167 androgen deprivation therapy Methods 0.000 claims description 4
- 230000003302 anti-idiotype Effects 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000003211 malignant Effects 0.000 claims description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 2
- 229960005190 Phenylalanine Drugs 0.000 claims description 2
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- 125000001116 prolino group Chemical group [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 101700011716 IL2RG Proteins 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675957P | 2018-05-24 | 2018-05-24 | |
| US62/675,957 | 2018-05-24 | ||
| PCT/IB2019/054184 WO2019224713A2 (en) | 2018-05-24 | 2019-05-21 | Monospecific and multispecific anti-tmeff2 antibodies and there uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021524255A JP2021524255A (ja) | 2021-09-13 |
| JPWO2019224713A5 true JPWO2019224713A5 (ru) | 2022-05-25 |
Family
ID=67211771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565399A Pending JP2021524255A (ja) | 2018-05-24 | 2019-05-21 | 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11866499B2 (ru) |
| EP (1) | EP3802607A2 (ru) |
| JP (1) | JP2021524255A (ru) |
| KR (1) | KR20210011999A (ru) |
| CN (1) | CN112703203A (ru) |
| AR (1) | AR115419A1 (ru) |
| AU (1) | AU2019274652A1 (ru) |
| BR (1) | BR112020023416A2 (ru) |
| CA (1) | CA3101304A1 (ru) |
| CL (1) | CL2020003032A1 (ru) |
| CO (1) | CO2020014515A2 (ru) |
| CR (1) | CR20200564A (ru) |
| EA (1) | EA202092849A1 (ru) |
| EC (1) | ECSP20075234A (ru) |
| IL (1) | IL278862A (ru) |
| JO (1) | JOP20200295A1 (ru) |
| MA (1) | MA52772A (ru) |
| MX (1) | MX2020012589A (ru) |
| NI (1) | NI202000087A (ru) |
| PE (1) | PE20210634A1 (ru) |
| PH (1) | PH12020551948A1 (ru) |
| SG (1) | SG11202011268VA (ru) |
| TW (1) | TW202003584A (ru) |
| UY (1) | UY38243A (ru) |
| WO (1) | WO2019224713A2 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023508A2 (pt) | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| CN115175702A (zh) * | 2019-12-18 | 2022-10-11 | 詹森生物科技公司 | 用于体内生物靶向的材料和方法 |
| AU2021356681A1 (en) * | 2020-10-09 | 2023-05-18 | Eureka Therapeutics Inc. | Compositions targeting ndc80/mhc complexes and uses thereof |
| CA3198590A1 (en) | 2020-10-13 | 2022-04-21 | Rajkumar Ganesan | Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii |
| WO2023164510A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
| WO2024052831A1 (en) * | 2022-09-09 | 2024-03-14 | Janssen Biotech, Inc. | Method of treating cancer with an anti tmeff2xcd3 bispecific antibody |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709A (en) | 1850-10-08 | Chas S Gaylord | Improved spring-grapple | |
| US226A (en) | 1837-06-03 | Samuel goss | ||
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| AU690528B2 (en) | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| JP2006502092A (ja) | 2002-03-08 | 2006-01-19 | プロテイン デザイン ラブス インコーポレイティド | ガン抗原ｔｍｅｆｆ２に対する抗体及びそれらの使用 |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| EP2069401A4 (en) | 2007-07-31 | 2011-02-23 | Medimmune Llc | MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP2347038A4 (en) | 2008-10-14 | 2013-06-12 | Janssen Biotech Inc | METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| KR102052774B1 (ko) | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| US20150030602A1 (en) * | 2011-12-23 | 2015-01-29 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
| DK3653049T3 (da) | 2012-12-14 | 2023-11-13 | Omniab Inc | Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse |
| KR102216003B1 (ko) | 2013-03-15 | 2021-02-16 | 얀센 바이오테크 인코포레이티드 | 재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법 |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| LT3189081T (lt) | 2014-09-05 | 2020-05-11 | Janssen Pharmaceutica Nv | Cd123 surišantys agentai ir jų naudojimas |
| EP3288981A1 (en) * | 2015-05-01 | 2018-03-07 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| JP2018526972A (ja) | 2015-06-16 | 2018-09-20 | ジェネンテック， インコーポレイテッド | 抗ｃｄ３抗体及び使用方法 |
| EP3370768B9 (en) * | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| KR20220080044A (ko) * | 2018-05-16 | 2022-06-14 | 얀센 바이오테크 인코포레이티드 | 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체 |
| BR112020023508A2 (pt) | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
-
2019
- 2019-05-21 SG SG11202011268VA patent/SG11202011268VA/en unknown
- 2019-05-21 US US16/417,889 patent/US11866499B2/en active Active
- 2019-05-21 PE PE2020001881A patent/PE20210634A1/es unknown
- 2019-05-21 WO PCT/IB2019/054184 patent/WO2019224713A2/en unknown
- 2019-05-21 CR CR20200564A patent/CR20200564A/es unknown
- 2019-05-21 CN CN201980034951.1A patent/CN112703203A/zh active Pending
- 2019-05-21 CA CA3101304A patent/CA3101304A1/en active Pending
- 2019-05-21 JO JOP/2020/0295A patent/JOP20200295A1/ar unknown
- 2019-05-21 EP EP19737217.0A patent/EP3802607A2/en active Pending
- 2019-05-21 MX MX2020012589A patent/MX2020012589A/es unknown
- 2019-05-21 AU AU2019274652A patent/AU2019274652A1/en active Pending
- 2019-05-21 JP JP2020565399A patent/JP2021524255A/ja active Pending
- 2019-05-21 BR BR112020023416-8A patent/BR112020023416A2/pt unknown
- 2019-05-21 MA MA052772A patent/MA52772A/fr unknown
- 2019-05-21 EA EA202092849A patent/EA202092849A1/ru unknown
- 2019-05-21 KR KR1020207036922A patent/KR20210011999A/ko active Search and Examination
- 2019-05-22 TW TW108117613A patent/TW202003584A/zh unknown
- 2019-05-24 AR ARP190101399A patent/AR115419A1/es unknown
- 2019-05-24 UY UY0001038243A patent/UY38243A/es unknown
-
2020
- 2020-11-13 PH PH12020551948A patent/PH12020551948A1/en unknown
- 2020-11-19 IL IL278862A patent/IL278862A/en unknown
- 2020-11-23 CO CONC2020/0014515A patent/CO2020014515A2/es unknown
- 2020-11-23 NI NI202000087A patent/NI202000087A/es unknown
- 2020-11-23 CL CL2020003032A patent/CL2020003032A1/es unknown
- 2020-11-23 EC ECSENADI202075234A patent/ECSP20075234A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| WO2018205985A1 (zh) | 含有TGF-β受体的融合蛋白及其医药用途 | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| RU2019123613A (ru) | Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9 | |
| JPWO2019224718A5 (ru) | ||
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| RU2012131547A (ru) | Антитела человека против ангиопоэтин-подобного белка 4 человека | |
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| JP7471016B2 (ja) | 抗ｃｄ７３抗体およびその適用 | |
| CA2189015A1 (en) | Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases | |
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| US20220041744A1 (en) | Cd73 blocking antibodies | |
| CN110090306B (zh) | 双醛连接臂的配体-药物偶联物、其制备方法及其应用 | |
| RU2014109093A (ru) | Антитела против нейрегулина и их применение | |
| JP2020522280A5 (ru) | ||
| JP2024016024A5 (ru) | ||
| AU2016319433A1 (en) | Anti-EphA4 antibody | |
| JP2020522281A5 (ru) | ||
| CN112334486A (zh) | 用于治疗癌症的组合物和方法 | |
| JPWO2019224717A5 (ru) | ||
| RU2014140116A (ru) | Антитела против pdgf-c | |
| JPWO2019224713A5 (ru) | ||
| WO2022127066A1 (zh) | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 | |
| US20230074657A1 (en) | Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof |